The Stability Problem: Why Some Recombinant Antibodies Don’t Make It to Market

Stability remains a critical determinant of success in therapeutic antibody development. In the context of recombinant antibodies, it encompasses physical, chemical, and biological stability, each influencing manufacturability, shelf life, safety, and clinical efficacy ^{1 2} Despite robust discovery pipelines, instability is a frequent cause of attrition, leading to project delays, reformulation efforts, or complete termination.

This article examines the mechanisms, causes, and consequences of antibody instability, outlining practical strategies to improve stability and advance promising candidates toward market approval. We explore why instability derails promising antibodies and how developers can mitigate these risks to safeguard their pipeline productivity.

Types of Instability Affecting Recombinant Antibodies

Stability challenges can arise at multiple levels, each undermining the efficacy, safety, and manufacturability of recombinant antibodies. Understanding the different types of instability is critical for identifying risks early and implementing targeted mitigation strategies.

Physical Instability

Physical instability is one of the most common hurdles faced during antibody development. It typically manifests as aggregation or precipitation during production, formulation, or storage ³. Aggregation is particularly problematic, as it not only reduces the effective concentration of the antibody but also increases the risk of immunogenicity when administered to patients. ⁴

For example, mAbs exposed to temperature fluctuations or mechanical stress during purification and filling operations can form high-molecular-weight aggregates. These aggregated forms are often difficult to remove and can trigger anti-drug antibody (ADA) responses, compromising safety and therapeutic efficacy.

Chemical Instability

Chemical instability includes degradation processes such as deamidation, oxidation, and isomerisation.^{5 6}Deamidation of asparagine residues, for instance, can alter local charge, reducing binding affinity to the target antigen. Oxidation of methionine or tryptophan residues can similarly affect structural integrity, leading to potency loss.

Moreover, chemical modifications can introduce heterogeneity that complicates analytical characterization and regulatory approval. Even if these changes occur at low rates, their cumulative impact during manufacturing, storage, and administration can undermine product safety and performance.

Biological Instability

Biological instability refers to degradation through proteolytic cleavage, either within the production host (e.g., CHO cells) or after administration. ^{7 8} In expression systems, endogenous proteases may cleave the antibody, reducing yields and increasing purification complexity. In vivo, proteolytic degradation shortens half-life, requiring higher dosing or more frequent administration to maintain therapeutic levels.

Such instability not only impacts pharmacokinetics and bioavailability but also introduces fragmented antibody species that may be immunogenic or lack intended function.

Causes of Instability in Recombinant Antibody Development

Identifying the underlying causes of antibody instability is crucial to guide engineering and process optimization efforts. These causes often stem from the molecular structure, formulation design, or manufacturing workflow.

Sequence Liabilities

Instability often originates at the molecular level. Certain sequence motifs or unstructured regions are intrinsically prone to degradation. For example, deamidation-prone asparagine residues, oxidation-susceptible methionines, and flexible loops can all compromise stability. ^{9 10} Without early sequence optimization, these liabilities persist throughout development, leading to failures during formulation, scale-up, or stability testing.

Suboptimal Formulation Conditions

Formulation buffers and excipients are critical to maintaining antibody stability. Inadequate buffering capacity, inappropriate pH, or the absence of stabilizing agents like polysorbates can accelerate aggregation and chemical degradation. Even small differences in excipient concentration can significantly impact stability profiles, underlining the importance of systematic formulation development.

Process-Induced Stress

Antibody production processes inherently impose stresses that challenge molecular stability. Shear stress during filtration, temperature shifts during purification, and concentration steps prior to fill-finish can induce aggregation or partial unfolding ⁸. Storage conditions, including exposure to light or suboptimal temperatures, further exacerbate these risks.

Consequences: Why Instability Leads to Project Termination

Instability has far-reaching implications for therapeutic antibody programs. From loss of potency to regulatory rejection, it is a common but preventable cause of attrition.

Loss of Potency and Efficacy

Instability directly compromises the therapeutic function of antibodies. Aggregation reduces the concentration of active monomer, chemical degradation alters binding affinity, and proteolysis destroys functional domains. Even if potency loss is partial, it can render a candidate nonviable, particularly if dose escalation is not feasible or introduces safety risks.

Increased Immunogenicity Risks

Aggregated or degraded antibodies are more likely to be recognized as foreign by the immune system, triggering ADA responses. ¹¹ Immunogenicity not only neutralizes therapeutic effects but can also cause adverse reactions, halting clinical development.

Regulatory Hurdles

Regulators require comprehensive stability data to approve therapeutic antibodies. Instability-related heterogeneity complicates analytical characterization and batch consistency, leading to delays or outright rejection. Additionally, poor stability increases production costs and complicates supply chain logistics, undermining commercial viability.

Strategies to Improve Antibody Stability

Improving antibody stability requires an integrated approach spanning molecular design, formulation development, and manufacturing optimization. Each strategy targets specific instability mechanisms to enhance therapeutic performance and ensure regulatory and commercial success.

Sequence Engineering

Targeted sequence modifications can dramatically improve stability. This includes removing deamidation-prone asparagine residues, replacing oxidation-sensitive methionines, and optimizing CDR frameworks for reduced hydrophobicity and aggregation risk. ¹²

Optimizing Formulation Buffers

Formulation scientists systematically screen buffer systems, pH ranges, and excipient combinations to stabilize antibodies during storage and administration. Strategies include adding surfactants to prevent surface adsorption or adjusting ionic strength to minimize aggregation.

Process Optimization

Process conditions such as temperature, shear stress, and concentration methods are optimized to minimize physical stress. Implementing gentler purification steps and designing manufacturing processes with stability in mind can reduce degradation risks significantly.

How evitria Supports Stability-Focused Development

At evitria, we understand that stability challenges are a major bottleneck in advancing antibody candidates to the clinic. Our recombinant antibody expression service is specifically designed to support stability-focused development by offering extensive experience with Fc engineering, glyco-engineering, bispecifics, and other advanced formats ensures that your candidates are expressed efficiently and with high stability, ready for further development.

We enable fast side-by-side stability assessments by producing multiple antibody variants within weeks, allowing developers to select the most stable candidates early and avoid costly re-engineering later in development.

Further, our team provides guidance on sequence modifications, Fc glycoengineering to improve stability and effector functions, and pairing technologies to optimize bispecific assembly and minimize degradation risks in our bispecific antibody production service.

References

1. Wang, Qiong et al. “Design and Production of Bispecific Antibodies.” Antibodies vol. 8,3 43. 2019. doi:10.3390/antib8030043 ↩︎
2. Ecker, Dawn M et al. “The therapeutic monoclonal antibody market.” mAbs vol. 7,1 (2015): 9-14. doi:10.4161/19420862.2015.989042 ↩︎
3. Bana, Arpit Arun K et al. “Physical Instabilities of Therapeutic Monoclonal Antibodies: A Critical Review.” Current Drug Discovery Technologies vol. 19,6 (2022). doi:10.2174/1570163819666220624092622 ↩︎
4. Svilenov, Hristo et al. “A New Approach to Study the Physical Stability of Monoclonal Antibody Formulations-Dilution From a Denaturant.” Journal of Pharmaceutical Sciences vol. 107,12 (2018): 3007-3013. doi:10.1016/j.xphs.2018.08.004 ↩︎
5. Basle, Y. et al. “Physicochemical Stability of Monoclonal Antibodies: A Review.” Journal of Pharmaceutical Sciences 109.1 (2020): 169–190. doi:10.1016/J.XPHS.2019.08.009 ↩︎
6. Ma, H. et al. “Antibody stability: A key to performance – Analysis, influences and improvement.” Biochimie 177 (2020): 213-225. doi:10.1016/j.biochi.2020.08.019 ↩︎
7. Ma, H. et al. “Antibody stability: A key to performance – Analysis, influences and improvement.” Biochimie 177 (2020): 213-225. doi:10.1016/j.biochi.2020.08.019 ↩︎
8. Ramezani, Vahid et al. “A comparative study on the physicochemical and biological stability of IgG1 and monoclonal antibodies during spray drying process.” Daru vol. 22,1 31. 2014. doi:10.1186/2008-2231-22-31 ↩︎
9. Paredes, Verenice et al. “Unstable expression of recombinant antibody during long-term culture of CHO cells is accompanied by histone H3 hypoacetylation.” Biotechnology Letters 35 (2013). doi:10.1007/s10529-013-1168-8 ↩︎
10. Dorai, Haimanti, et al. “Early prediction of instability of Chinese hamster ovary cell lines expressing recombinant antibodies and antibody‐fusion proteins.” Biotechnology and Bioengineering 109.4 (2012): 1016-1030. ↩︎
11. Akbarian, Mohsen, and Shu-Hui Chen. “Instability Challenges and Stabilization Strategies of Pharmaceutical Proteins.” Pharmaceutics vol. 14,11 2533. 2022. doi:10.3390/pharmaceutics14112533 ↩︎
12. Wang, Bo et al. “Optimization of therapeutic antibodies.” Antibody Therapeutics vol. 4,1 45-54. 2021. doi:10.1093/abt/tbab003 ↩︎